Drugmaker Eli Lilly said on Tuesday it is launching an artificial intelligence and machine learning platform that provides biotech companies access to drug discovery models trained on years of its research data. Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results, in line with an FDA push to reduce animal testing in the near future. Earlier in the year, Jefferies analysts had pegged AI-related research and development